KZA Chart, page-227

Yeah fun for trends when news is on but this is driven largely by news events still and will be until a steady stream of revenues is flowing...

it’s a pre-revenue biotech - with the license deals in place we will trigger payments through clinical trial milestones... new lic deals etc.

and with 7 trials underway we just don’t know when the news that fundamentally rewrites price will land - the company and investors will have plans around this but it will drop when it does.